Foreword: Hadron TherapyFrom Yesterday's Physics Laboratory to
Today's Modern Clinical Routine www.tcrt.org
Progress in radiation therapy is, and has always been, driven by the desire to improve tumor control and to reduce normal tissue complications. There are three parts to achieve this goal: improve imaging for diagnosis, treatment planning and delivery to allow a more accurate definition and delineation of target volumes; increase our ability to shape the dose deposition pattern inside the patient; and increase the biological effect of the energy deposited in the tumor.
Hadron therapy aims at the last two parts.
Ideas for medical applications of hadron radiation emerged soon after the discovery of the neutron in 1932 by James Chadwick. The first use of neutrons in a medical application was reported in 1938 (1). The concept was to take advantage of the elevated biological effectiveness in cell kill of neutrons. Similarly, many other radiation modalities, once discovered, were first used in physics experiments followed by biological experiments and finally at least considered for the treatment of cancerous neoplasm.
Boron neutron capture therapy (BNCT) was already conceptualized in 1936 (2) and its first reported use dates from 1952 (3). The concept in BNCT is the selective targeting of high linear energy transfer (LET) radiation to the tumor while sparing normal surrounding tissue. Of particular interest was the potential to deliver high-LET radiation to micrometastatic sites embedded in normal tissues and enhancing the targeting selectivity through preferential uptake of Boron by the diseased cells. Coderre et al. summarize the key issues of BNCT in a comprehensive review, describe the latest developments and discuss a roadmap for the successful use of BNCT for cancer treatment.
Robert Wilson first proposed the use of protons for radiation therapy at Harvard in 1946 (4). Wilson's rationale was the dose deposition characteristic of protons, i.e., the Bragg peak that exhibits the well-defined dose localization properties unique to hadrons. The first patient was treated in 1954 at Lawrence Berkeley Laboratory (5) and more than 30,000 patients have received proton therapy to date worldwide (6). The paper by Paganetti on the relative biological effectiveness (RBE) of protons has an introduction about proton radiation therapy in general and reviews the present status of the knowledge about proton radiobiology together with its clinical significance and implementation. The paper by Bussiere and Adams reviews the general treatment planning process for proton therapy as well as issues regarding patient set-up and patient-specific treatment hardware. Finally pions must be mentioned as a modality for radiation therapy (8) with the first use for patient treatment in 1974 (9). However, results where not encouraging and pion therapy has effectively been disregarded as a viable modality.
Most innovative techniques do not aim to replace standard photon radiation therapy. Instead they serve as an alternative or adjunct for specific sites or cancers where improved dose distributions or elevated biological effects lead to a significantly higher tumor control or significantly lower normal tissue complication. Many techniques could eventually find their way into clinical practice and used side-by-side with others. Eventually, different treatment strategies may not lead to a treatment of choice in general but to a patient specific treatment of choice.
As stated in the introductory historical remarks, most of the hadron therapy modalities have been available without making a big impact on radiation therapy. This is mainly because hadron radiation beams where only available at physics research laboratories not affiliated with hospitals. Modern technology transfer driven by scientists working in interdisciplinary projects and the fact that hospitals and patients demand the best technology leads to a productive method to bring new technology into the clinical environment. However, the example of neutron therapy serves as a reminder that technology by itself does not suffice and that a complete understanding of the physical and biological properties of a radiation modality is prerequisite for patient use. Some of the mentioned treatment modalities are still used in research labs and only some are established in clinical practice. The most important driving force is certainly the maturity of new treatment options shown in clinical trials that are underway for all modalities discussed in this journal issue. Eventually, hospitals will be able to purchase these technologies, and the required support, from vendors. This stage has already been reached for proton therapy where most patients today are treated at hospital-based facilities.
The future of hadron therapy looks bright, in particular for proton and heavy ion therapy. Several facilities are up and running and several other facilities are being built or planned (6). Protons are widely accepted in the radiation oncology community and have been proven to be superior to photons, even when considering intensity modulated radiotherapy, for several tumor sites. A critical issue is the cost of patient treatment (10). This however, may only be a function of the number of facilities being built.
